These results imply that each FOXF1 DNA binding domain mutant may have different effects on the regulation of target genes, depending on the DNA-binding motif present in the promoter region, which adds complexity to the development of ACD/MPV and may explain the phenotypic heterogeneity observed in patients. The gene discussed is FOXF1; the disease is granular corneal dystrophy type II.